Click here to register or learn more!
Presenter: Hannah Nakamura, PharmD
Clinical Toxicology Fellow
Arizona Drug & Poison Information Center
Description: This continuing education presentation reviews the pharmacologic principles of opioid medications, including their mechanisms of action, receptor interactions, and common therapeutic and adverse effects. Participants will also explore agents used for opioid reversal, with an emphasis on indications, mechanisms, and clinical considerations for their use in overdose. Additionally, opioid-equivalent dosing and morphine milligram equivalents (MME) will be reviewed to support safe opioid conversion, dosing adjustments, and improved prescribing practices.
Learning Objectives:
- Describe the mechanisms of action, receptor activity, pharmacokinetics, and adverse effects of commonly used opioid medications.
- Apply opioid-equivalent dosing principles to support safe opioid conversion and dosing adjustments in clinical practice.
- Compare available opioid antagonists used to reverse overdose including indications, dosing, onset/duration, and clinical considerations.
Continuing Medical Education
Accreditation Statement:
The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Arizona College of Medicine - Tucson designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Relevant Financial Relationships Statement(s):
University of Arizona College of Medicine - Tucson Office of Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.
